樂普生物-B(02157.HK)治療鼻咽癌藥物臨床完成全體受試者入組 股價曾升逾7%
樂普生物-B(02157.HK)公布,其候選藥物MRG003,近期已順利完成關鍵註冊性IIb期臨床試驗的全體受試者入組,用於治療復發性或轉移性鼻咽癌(R/M NPC)。
MRG003為一種表皮生長因子受體(EGFR)靶向抗體藥物偶聯物(ADC)候選藥物以及公司的核心產品。
該試驗為隨機、開放、多中心關鍵註冊性IIb期臨床研究,於今年4月啟動受試者入組,截至目前,173名受試者已順利完成入組。
樂普生物今日(29日)早段股價曾升7.3%高見4.27元,現報4.15元,升4.3%,成交88.2萬股,涉資369.58萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.